[go: up one dir, main page]

WO2002089828A3 - Interferons in the treatment of ischemia - Google Patents

Interferons in the treatment of ischemia Download PDF

Info

Publication number
WO2002089828A3
WO2002089828A3 PCT/EP2002/003758 EP0203758W WO02089828A3 WO 2002089828 A3 WO2002089828 A3 WO 2002089828A3 EP 0203758 W EP0203758 W EP 0203758W WO 02089828 A3 WO02089828 A3 WO 02089828A3
Authority
WO
WIPO (PCT)
Prior art keywords
ischemia
interferon
interferons
treatment
glycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/003758
Other languages
French (fr)
Other versions
WO2002089828A2 (en
Inventor
Yin Hwee Tan
Hubertus Schellekens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Molecular and Cell Biology
Original Assignee
Institute of Molecular and Cell Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0111070A external-priority patent/GB0111070D0/en
Priority claimed from GB0118023A external-priority patent/GB0118023D0/en
Application filed by Institute of Molecular and Cell Biology filed Critical Institute of Molecular and Cell Biology
Priority to AU2002310922A priority Critical patent/AU2002310922A1/en
Publication of WO2002089828A2 publication Critical patent/WO2002089828A2/en
Publication of WO2002089828A3 publication Critical patent/WO2002089828A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ischemia may be prevented or treated by administering an interferon such as human β-interferon. The β-interferon may be a glycosylated β-interferon. The ischemia may be cerebral or myocardial ischemia. In this way, the condition of a patient suffering from ischemia may be improved.
PCT/EP2002/003758 2001-05-04 2002-04-04 Interferons in the treatment of ischemia Ceased WO2002089828A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002310922A AU2002310922A1 (en) 2001-05-04 2002-04-04 Interferons in the treatment of ischemia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0111070.9 2001-05-04
GB0111070A GB0111070D0 (en) 2001-05-04 2001-05-04 Treatment of cerebral ischemia
GB0118023A GB0118023D0 (en) 2001-07-24 2001-07-24 Treatment of ischemia
GB0118023.1 2001-07-24

Publications (2)

Publication Number Publication Date
WO2002089828A2 WO2002089828A2 (en) 2002-11-14
WO2002089828A3 true WO2002089828A3 (en) 2003-02-06

Family

ID=26246039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003758 Ceased WO2002089828A2 (en) 2001-05-04 2002-04-04 Interferons in the treatment of ischemia

Country Status (2)

Country Link
AU (1) AU2002310922A1 (en)
WO (1) WO2002089828A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519946A (en) * 2002-03-12 2005-07-07 マキシジェン エーピーエス Interferon beta-like molecules for treatment of seizures
PL1608400T3 (en) 2003-03-28 2010-11-30 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (en) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Coagulation factor VII-Fc chimeric proteins for the treatment of hemostatic diseases
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
FI20051003A0 (en) * 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy A method of treating or preventing an ischemic reperfusion injury or multiple organ disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367735A1 (en) * 1988-09-30 1990-05-09 Göran Hansson Use of gamma interferon in pharmaceutical preparations for the treatment of vascular stenosis
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
WO1996030531A1 (en) * 1995-03-24 1996-10-03 Institute Of Molecular And Cell Biology Gene expression in mammalian cells
JPH09151137A (en) * 1995-12-01 1997-06-10 Toray Ind Inc Medicine for inhibiting multiplication of smooth muscle cell
EP0797998A1 (en) * 1995-11-17 1997-10-01 Toray Industries, Inc. Endothelial cell protective
WO1999051260A2 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Treatment of cardiac hypertrophy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367735A1 (en) * 1988-09-30 1990-05-09 Göran Hansson Use of gamma interferon in pharmaceutical preparations for the treatment of vascular stenosis
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
WO1996030531A1 (en) * 1995-03-24 1996-10-03 Institute Of Molecular And Cell Biology Gene expression in mammalian cells
EP0797998A1 (en) * 1995-11-17 1997-10-01 Toray Industries, Inc. Endothelial cell protective
JPH09151137A (en) * 1995-12-01 1997-06-10 Toray Ind Inc Medicine for inhibiting multiplication of smooth muscle cell
WO1999051260A2 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Treatment of cardiac hypertrophy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GROSS C.E. ET AL.: "Delayed tissue-plasminogen activator therapy in a rabbit model of thromboembolic stroke", NEUROSURGERY, vol. 36, no. 6, 1995, pages 1172 - 1177, XP001096147 *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 10 31 October 1997 (1997-10-31) *

Also Published As

Publication number Publication date
AU2002310922A1 (en) 2002-11-18
WO2002089828A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
WO2003015697A3 (en) Interleukin-2 mutants with reduced toxicity
WO1999052515A3 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
WO2002032414A3 (en) Ribavirin-pegylated interferon alfa hcv combination therapy
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
PL366619A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2001045712A8 (en) Combinations of medicaments for treating viral diseases
WO2002076494A3 (en) USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2003039444A3 (en) Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2002089828A3 (en) Interferons in the treatment of ischemia
CA2436572A1 (en) Perylenequinones for use as photosensitizers and sonosensitizers
WO2003018606A3 (en) Casein derived peptides and uses thereof in therapy
WO2003039468A3 (en) Antimnemonic therapy for hypermemory syndromes
EP1374887A4 (en) Novel agents for ameliorating motor disorder
MXPA03008393A (en) Bicyclic guanidine derivatives and therapeutic uses thereof.
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2002060382A3 (en) Novel compounds and uses thereof
WO2003059387A3 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
AU2003263978A1 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP